Since the 1980s, the prevalence of obesity has almost doubled worldwide. Treatments for obesity include lifestyle modification, medications and surgery. Newer anti-obesity medications have been shown to be effective at inducing initial weight management in addition to successful long-term weight maintenance. Historically, weight management medications have been associated with public safety concerns that have resulted in the majority being withdrawn from the market or never receiving medicinal authorization. Recently, several countries have approved some newer generation weight management medications which may be beneficial to combat obesity. These medications have varying effects on cardiometabolic parameters, both positive and potentially negative. This review will outline the mechanisms of action of these medications and their implications for both diabetes and cardiovascular risks.
CITATION STYLE
Wharton, S., & Serodio, K. J. (2015, May 1). Next Generation of Weight Management Medications: Implications for Diabetes and CVD Risk. Current Cardiology Reports. Current Medicine Group LLC 1. https://doi.org/10.1007/s11886-015-0590-z
Mendeley helps you to discover research relevant for your work.